<?xml version="1.0" encoding="UTF-8"?>
<p id="Par61">The COVID-19 pandemic has undoubtedly uncovered the strengths of global collaborations, effective communication, and dissemination of information. Unless we prepare and foresee the likely new set of RMDs and the possible mimics of RMDs [
 <xref ref-type="bibr" rid="CR8">8</xref>] due to this pandemic, we are going to fail in delivering care to our patients. We have recently learned the costs of being underprepared when challenged with the rheumatological manifestation [
 <xref ref-type="bibr" rid="CR9">9</xref>] resulting from the use of immune checkpoint inhibitors in cancer treatment. The initial dilemma on the management plan and prognosis of these conditions set the rheumatology community on a backfoot [
 <xref ref-type="bibr" rid="CR10">10</xref>]. Keeping this context in mind, it is time to pool all our existing knowledge and resources to prepare for any rheumatological fallout of COVID-19 and its treatment, which may have left behind its footprints even in the post-COVID-19 era.
</p>
